roivant sciences ltd glp-1 receptor agonist medications New Guidelines for Type 2 Diabetes in 2025 GLP Agonist Clinical Trial Pipeline
Description
MOUNJARO / ZEPBOUND (TIRZEPATIDE) This one is a step up in terms of mechanism
The SURPASS and SURMOUNT trials have led the ADA to consider tirzepatide, along with semaglutide, to be very highly efficacious for weight loss [38]
As nausea is a common side effect, dietary changes should be reviewed vigilantly
And globally, the market is expected to expand at a similar pace
What Results Are Realistic
Telehealth intake
